文献速递老年慢病共病管理认知障碍与谵妄

认知正常老年人多重共病与临床前阿尔茨海默病阶段及疑似非淀粉样病理的关联

The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2019-01-01

研究纳入梅奥诊所衰老研究中1535名认知正常且有多重共病(≥2种慢性病)的参与者,采用11C-PiB PET和MRI定义生物标志物分组。结果显示多重共病与A+N+及A-N+(神经退行性变伴或不伴淀粉样沉积)显著相关,且慢性病数量与上述分组存在剂量反应关系。

要点

  • 多重共病与神经退行性变生物标志物组合(A+N+、A-N+)显著相关。
  • 慢性病数量增加与A+N+和A-N+的 odds 呈剂量反应关系。
  • 关联需在纵向研究中验证。

核心结论

  • 多重共病与包含神经退行性变(伴或不伴淀粉样沉积)的生物标志物组合相关。

研究设计与样本

  • 横断面研究,纳入梅奥诊所衰老研究中1535名认知正常且有多重共病的参与者(≥50岁),具备11C-PiB PET和MRI数据。

主要发现

  • A+、N+、A+N+和A-N+生物标志物组的频率随慢性病数量增加而显著增加。
  • 多重共病与A+N+(对比A-N-)显著相关,OR 1.76,95%CI 1.02-2.90。
  • 多重共病与A-N+(对比A-N-)显著相关,OR 2.16,95%CI 1.47-3.18。
  • 慢性病数量(如0-1、2-3、4+)与A+N+和A-N+(对比A-N-)的 odds 存在剂量反应关系。

关键数值与推荐

  • 多重共病定义为≥2种慢性病。
  • A+定义为11C-PiB PET保留比值异常升高(标准化摄取值比>1.42)。
  • N+定义为阿尔茨海默病特征性皮层厚度异常减低(<2.67 mm)。

临床怎么用

  • 在认知正常老年人中,多重共病提示神经退行性变生物标志物异常的风险增高,可考虑作为临床前AD风险评估的参考信息。

局限性

  • 横断面设计无法确定因果关系。
  • 作者指出关联需在纵向研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multimorbidity (defined as ≥2 chronic conditions) has been associated with increased risk of mild cognitive impairment and cross-sectionally with imaging biomarkers of neurodegeneration in cognitively unimpaired persons aged ≥70 years. Its association with preclinical Alzheimer's disease stages has not been studied in detail yet. The objective of the study was to assess the cross-sectional association of multimorbidity with preclinical Alzheimer's disease stages and suspected non-amyloid pathophysiology in cognitively unimpaired participants of the Mayo Clinic Study of Aging (≥50 years of age). METHODS: The study included 1,535 cognitively unimpaired participants with multimorbidity, 11C-PiB positron emission topography and magnetic resonance imaging data available. Abnormal (elevated) 11C-PiB-positron emission topography retention ratio (A+; standardized uptake value ratio >1.42) and abnormal (reduced) Alzheimer's disease signature cortical thickness (N+; <2.67 mm) were used to define biomarker combinations (A-N-, A+N-, A-N+, A+N+). Chronic medical conditions were ascertained by using the Rochester Epidemiology Project medical records linkage system and International Classification of Diseases criteria. Cross-sectional associations were examined using multinomial logistic regression models adjusting for age, sex, education, and apolipoprotein E ɛ4 allele status. RESULTS: Frequency of A+, N+, A+N+, and A-N+ biomarker groups increased significantly with increasing number of chronic conditions. Multimorbidity was significantly associated with A+N+ (vs A-N-; odds ratio, 1.76, 95% confidence interval 1.02, 2.90) and A-N+ (vs A-N-; odds ratio, 2.16, 95% confidence interval 1.47, 3.18). There was a dose-response relationship between increasing number of chronic conditions (eg, 0-1, 2-3, and 4+) and the odds of A+N+ and A-N+ (vs A-N-). CONCLUSIONS: Multimorbidity was associated with biomarker combinations that included neurodegeneration with or without elevated amyloid deposition (ie, A-N+, A+N+). The associations should be validated in longitudinal studies.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Vassilaki M, Aakre JA, Kremers WK, et al. The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. J Gerontol A Biol Sci Med Sci. 2019. PMID: 30124772. doi:10.1093/gerona/gly149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。